LifeVantage Corp. Announces Director Changes and Officer Compensation
Ticker: LFVN · Form: 8-K · Filed: Aug 26, 2024 · CIK: 849146
| Field | Detail |
|---|---|
| Company | Lifevantage Corp (LFVN) |
| Form Type | 8-K |
| Filed Date | Aug 26, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $105,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
Related Tickers: LFVN
TL;DR
LFVN board shakeup: Director out, new director in, officer pay details coming.
AI Summary
LifeVantage Corp. announced on August 26, 2024, the departure of Director Michael J. Stewart and the appointment of new Director Dr. Steven G. Stevanov. The company also disclosed compensatory arrangements for certain officers, though specific details and dollar amounts were not provided in this initial filing.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Director changes and undisclosed compensatory arrangements introduce a degree of uncertainty regarding the company's internal dynamics and future financial commitments.
Key Players & Entities
- LifeVantage Corp. (company) — Registrant
- Michael J. Stewart (person) — Departing Director
- Dr. Steven G. Stevanov (person) — Newly Appointed Director
FAQ
Who has been appointed as a new director to LifeVantage Corp.'s board?
Dr. Steven G. Stevanov has been appointed as a new director.
Who has departed from LifeVantage Corp.'s board of directors?
Michael J. Stewart has departed from the board of directors.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is August 26, 2024.
What is LifeVantage Corp.'s Standard Industrial Classification code?
LifeVantage Corp.'s Standard Industrial Classification code is 2834, Pharmaceutical Preparations.
What specific compensatory arrangements for officers are mentioned in the filing?
The filing mentions compensatory arrangements of certain officers but does not provide specific details or dollar amounts in this initial report.
Filing Stats: 778 words · 3 min read · ~3 pages · Grade level 12 · Accepted 2024-08-26 16:26:04
Key Financial Figures
- $0.0001 — ) of the Act: Common Stock, par value $0.0001 LFVN The Nasdaq Stock Market LLC Title
- $105,000 — of the Company's common stock equal to $105,000 divided by the average closing price of
Filing Documents
- lfvn-20240826.htm (8-K) — 29KB
- lfvn-pressreleasedirector.htm (EX-99.1) — 13KB
- image_0a.jpg (GRAPHIC) — 15KB
- 0000849146-24-000064.txt ( ) — 191KB
- lfvn-20240826.xsd (EX-101.SCH) — 2KB
- lfvn-20240826_lab.xml (EX-101.LAB) — 22KB
- lfvn-20240826_pre.xml (EX-101.PRE) — 13KB
- lfvn-20240826_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Form of Indemnification Agreement (incorporated by reference to Exhibit 99.1 to Form 8-K filed with the SEC on March 13, 2018). 99.1 Press Release issued August 26, 2024 announcing the resignation of Erin Brockovich from and the appointment of Rajendran Anbalagan as a member of the Company's Board of Directors. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: August 26, 2024 LIFEVANTAGE CORPORATION By: /s/ Steven R. Fife Name: Steven R. Fife Title: President and Chief Executive Officer